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Dhyanesh A. Patel1, Hannah P. Kim1, Jerry S. Zifodya1 and Michael F. Vaezi2*Abstract
Idiopathic achalasia is a primary esophageal motor disorder characterized by loss of esophageal peristalsis and
insufficient lower esophageal sphincter relaxation in response to deglutition. Patients with achalasia commonly
complain of dysphagia to solids and liquids, bland regurgitation often unresponsive to an adequate trial of proton
pump inhibitor, and chest pain. Weight loss is present in many, but not all patients. Although the precise etiology is
unknown, it is often thought to be either autoimmune, viral immune, or neurodegenerative. The diagnosis is based
on history of the disease, barium esophagogram, and esophageal motility testing. Endoscopic assessment of the
gastroesophageal junction and gastric cardia is necessary to rule out malignancy. Newer diagnostic modalities such
as high resolution manometry help in predicting treatment response in achalasia based on esophageal pressure
topography patterns identifying three phenotypes of achalasia (I-III) and outcome studies suggest better treatment
response with types I and II compared to type III. Although achalasia cannot be permanently cured, excellent
outcomes are achieved in over 90 % of patients. Current medical and surgical therapeutic options (pneumatic
dilation, endoscopic and surgical myotomy, and pharmacologic agents) aim at reducing the LES pressure and
facilitating esophageal emptying by gravity and hydrostatic pressure of retained food and liquids. Either graded
pneumatic dilatation or laparoscopic surgical myotomy with a partial fundoplication are recommended as initial
therapy guided by patient age, gender, preference, and local institutional expertise. The prognosis in achalasia
patients is excellent. Most patients who are appropriately treated have a normal life expectancy but the disease
does recur and the patient may need intermittent treatment.
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Idiopathic achalasia (ORPHA930) is a primary esopha-
geal motility disorder of unknown etiology characterized
manometrically by esophageal aperistalsis and insuffi-
cient relaxation of the lower esophageal sphincter (LES)
in response to deglutition [1–5]. It is a rare disease with
an annual incidence of approximately 2/100,000 and a
prevalence rate of 10/100,000 [6]. Studies have shown
that incidence and prevalence of the disease are increas-
ing [7, 8] and the peak incidence occurs between 30 and
60 years of age [7]. Achalasia was first described and
termed by Sir Thomas Willis in 1674, when he suggested
that the disease is due to the loss of normal inhibition in
the distal esophagus [9]. Since then, the development of
new diagnostic techniques stimulated new ideas about
the etiology and pathophysiology of the disease leading* Correspondence: Michael.vaezi@vanderbilt.edu
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disturbances in esophageal regions. However, the initiat-
ing cause is still unclear [3, 9, 10].
In this review article we provide current insight on the
pathogenesis, etiology, diagnosis, and treatment options
for this motor disorder of the esophagus.Clinical description
Achalasia is one of the most investigated motor disor-
ders of the esophagus [4, 10]. The disease can occur at
any age but it is usually diagnosed between 30 and
60 years. Progressive dysphagia to solids followed by liq-
uids (82 %-100 %) is the first clinical symptom of achala-
sia [11]. Although dysphagia can occur in patients with
other esophageal motility disorders, this symptom is
most characteristic of achalasia and strongly suggests
the diagnosis.
Regurgitation not responding to adequate proton
pump inhibitor (PPI) therapy and weight loss can be
seen in 30 % to 90 % of patients. Regurgitation ofcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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during supine position at night, may lead to aspiration.
There is no universal definition for “adequate” PPI ther-
apy, however, based on recent gastro-esophageal reflux
disease (GERD) guidelines, it has been taken to consti-
tute ensuring compliance, optimal dosing, changing to a
different PPI, and possibly BID dosing [12]. Chest pain is
another presenting symptom of achalasia (17 %-95 %).
The occurrence of this symptom is unrelated to the LES
pressure [4, 11]. Chest pain has been found to be more
frequent in younger patients and in female patients who
have achalasia [4, 13–15]. In addition, 40 % of patients
with achalasia report occurrence of at least one respira-
tory symptom daily, including cough (37 %), hoarseness
(21 %), wheezing (15 %), shortness of breath (10 %), and
sore throat (12 %) [16].
Heartburn, the main symptom of GERD, may also
occur infrequently (27 %-42 %) in achalasia patients.
The mean LES pressure in patients with achalasia who
experience heartburn has been reported to be signifi-
cantly lower than that in patients without heartburn
[17]. Weight loss (usually between 5 and 10 kg) is
present in most but not all patients. Difficulty belching
has also been reported in up to 85 % of the patients, and
is due to a defect in relaxation of the upper esophageal
sphincter in these patients [1, 18].
Etiology
The distal esophageal wall and LES are innervated by
postganglionic neurons, consisting of excitatory and in-
hibitory neurons. The excitatory neurons release acetyl-
choline while the inhibitory neurons release nitric oxide
(NO) and vasoactive intestinal polypeptide (VIP), result-
ing in esophageal and LES contractions and relaxations,
respectively [3]. The NO and VIP releasing inhibitory
neurons are the target in idiopathic achalasia. Loss of
these inhibitory neurons due to either intrinsic or extrin-
sic causes will result in the manometric consequence of
failure of LES relaxation and loss of esophageal peristal-
sis [3, 4, 19].
Several studies on humans and animals [20, 21] have
suggested that extrinsic causes such as lesions located in
the central nervous system (CNS) may produce mano-
metric findings of achalasia. Abnormalities of the vagal
nerve fibers outside the CNS has also been associated
with achalasia; however, extrinsic innervation abnormal-
ities are rare findings in achalasia patients [22–24] and
are thus probably not the primary mechanism of the dis-
ease. In contrast, intrinsic loss of inhibitory myenteric
neurons in both the esophagus and LES has been re-
ported as the most likely contributory factor in the
pathophysiology of achalasia. Studies [25–27] have sug-
gested that loss of VIP and NO secreting neurons leads
to an imbalance between the excitatory and inhibitoryneurons of the myenteric plexus, producing irreversible
manometric changes in such patients. Morphologic
studies of the esophageal myenteric plexus have also
confirmed the loss of myenteric ganglion cells in achala-
sia [28, 29]. In such studies, loss of ganglion cells was as-
sociated with inflammation and in severe cases, the
myenteric nerves had been replaced by collagen.
Genetic
The existence of familial cases suggest that achalasia is an
inherited disease [30–33]. Such familial cases have been
mostly seen in the pediatric population, between siblings
and in a few cases in monozygotic twins [30, 31]. Achalasia
has been associated with Allgrove (Triple-A) syndrome,
Down’s syndrome, and congenital central hypoventilation
syndrome [34].
Mutation of the ALADIN 12q13 gene is a commonly
reported cause of achalasia in children. It leads to the
development of Allgrove syndrome, also known as
Triple-A syndrome, which is an autosomal disease char-
acterized by adrenocorticotropin hormone (ACTH) re-
sistant adrenal insufficiency, achalasia, and alacrima [35].
Furthermore, 77 % of children with Down’s syndrome
have gastrointestinal abnormalities with 2 % developing
achalasia [36]. Recent studies have also shown multiple
genetic mutations such as nitric oxide synthase 1 gene
(NOS1), VIP receptor 1, IL23R, IL10 promoter, IL33,
and protein tyrosine phosphatase non-receptor 22
(PTPN22) to be associated with the development of
achalasia [37–43]. It is proposed that genetic predispos-
ition in such individuals probably increases their suscep-
tibility to acquiring achalasia after exposure to common
environmental factors that may play a role in the patho-
genesis [2].
Infection
Several studies have suggested a possible association be-
tween viral infections and achalasia [44, 45]. In these
studies, various viral antibodies were measured in the
serum of patients with achalasia and in normal controls.
Measles and varicella zoster virus antibodies were found
to be higher among a number of patients with achalasia
[3]. Studies using polymerase chain reaction (PCR) dem-
onstrated no evidence of viral products in esophageal
tissue of patients with achalasia [46, 47]. More recently,
Castaglinolo et al. demonstrated HSV-1 reactive im-
mune cells in LES muscles of patients with achalasia
[48]. Though HSV-1 may be also found in patients’ with-
out achalasia, the presence of these immune reactive
cells directed at the virus suggests HSV-1 may play a
role in genetically susceptible individuals. A role for
HSV-1 was further demonstrated by Facco et al. who
demonstrated increased T cell proliferation and T
helper-1 type cytokines release in response to HSV-1
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laparoscopic myotomy of 59 patients with idiopathic
achalasia [49]. Thus, although the infectious etiology of
achalasia remains an unclear matter, there is mounting evi-
dence suggesting an immune-mediated inflammatory dis-
ease in which latent HSV-1 infection leads to persistent
immune activation and eventual self-destruction of esopha-
geal neurons in genetically susceptible patients [50].
Autoimmune
Increased prevalence of circulating antibodies against
myenteric plexus in some patients with achalasia led to
the suggestion of a role for auto-antibodies in the patho-
genesis of this disease [51, 52]; however, a recent study
by Moses et al. [53] suggested that these circulatory
antibodies are most likely the result of a nonspecific re-
action to the disease process instead of being the cause
of the disease. This idea was supported by detection of
similar antibodies in patients without achalasia. A recent
study did find that patients with achalasia were 3.6×
more likely to have autoimmune diseases including Sjog-
ren’s syndrome, uveitis, systemic lupus erythematosus,
type I diabetes, and hypothyroidism [54].
Ultra-structural studies [55, 56] of the esophageal tis-
sue of patients with achalasia have also found inflamma-
tory infiltrates around myenteric neurons, while in
control groups normal myenteric plexus was found with-
out infiltration. Multiple case–control studies [57–60]
have reported a significant association with HLA class II
antigens in idiopathic achalasia. A recent study [60] also
showed that achalasia patients with the associated HLA al-
lele had a higher prevalence of circulating anti-myenteric
autoantibodies, which supports the autoimmune etiology
theory [3]. HLA association also suggests immunogenetic
predisposition for idiopathic achalasia.
Overall, etiology behind the development of achalasia
is likely multifactorial and continues to be highly investi-
gated. Several genes and autoimmune disorders have
been associated with achalasia as outlined above. It is
proposed that genetic predisposition probably increases
the likelihood of triggering autoimmune mechanisms
after exposure to viruses or other common environmen-
tal factors [61].
Diagnosis
The diagnosis of idiopathic achalasia is relatively straight-
forward with a well-documented medical history, radiog-
raphy, and esophageal motility testing.
History
In the early stages of the disease, dysphagia may be very
subtle and can be misinterpreted as dyspepsia, poor gas-
tric emptying, or stress. The presence of heartburn due
to food stasis can add to this confusion. As the diseaseprogresses, difficulty swallowing characteristically occurs
with both solids and liquids and is often associated with
regurgitation of bland undigested food or saliva [5]. The
dysphagia is more to solids than liquids. To ease pro-
gression of the food bolus, patients usually modify their
eating habits: eating more slowly or using certain ma-
neuvers such as raising the arms or arching the back.
Esophageal manometry
Manometry is the gold standard for establishing the
diagnosis of achalasia and is essential for the diagnosis
regardless of the findings on barium esophagram and
esophagogastroduodenoscopy (EGD). The manometric
findings of aperistalsis and incomplete LES relaxation is
characteristic on conventional manometry. Wet and dry
swallows are followed by simultaneous contractions [1].
The amplitude of the contractions is low (10–40 mm
Hg) and repetitive in most cases [9] (Fig. 1). The LES
displays high pressure at rest and fails to relax, or relaxes
only partially with swallowing (Fig. 1). Up to 40 % of the
patients with achalasia have normal LES pressure
(10–40 mm Hg); however, low pressure LES is not
seen in untreated achalasia patients [62].
Aperistalsis is defined as lack of propagating esopha-
geal contractile activity and presents with different pres-
sure patterns including quiescent esophageal body (Type
I), isobaric pan-esophageal pressurization (Type II), or
simultaneous contractions (Type III), and can now be
easily identified with high-resolution manometry (HRM)
(Fig. 2) [63]. Although both conventional manometry or
HRM can be used for diagnosis, new data is emerging to
suggest that HRM may have increased sensitivity in
diagnosing achalasia compared to conventional manom-
etry techniques [64]. More importantly, new space-time
analysis paradigms with HRM that portrays the pressure
signal through the esophagus in a seamless dynamic
space-time continuum in the form of esophageal pres-
sure topography can help characterize the motor pat-
terns with treatment outcome implications. Based on
three retrospective studies, subtype II has the best prog-
nosis, whereas subtype I is somewhat lower and subtype
III can be difficult to treat [63, 65, 66].
Timed barium esophagogram
Barium swallow was initially used by Vantrappen et al.
[67] in achalasia patients to determine the cause of per-
sistent symptoms after treatment with pneumatic dilation.
The characteristics of achalasia in barium esophago-
gram are the loss of primary peristalsis in the distal
two third of the esophagus, and poor emptying with
retained food and saliva producing an air-fluid level at
the top of the barium column. In chronic stages of
the disease, there is a dilated esophagus or sigmoid
tortuosity and sometimes, in advanced cases, massive
Fig. 1 a) Conventional water perfused manometric findings of classic achalasia. Isobaric simultaneous esophageal body contractions (lower four
tracings) with incomplete LES relaxation (upper most tracing). b) High resolution manometry (HRM) findings in achalasia (simultaneous pan
esophageal pressurization with incomplete LES relaxation)
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tions for treatment [1, 5]. The typical finding in acha-
lasia is the presence of smooth tapering of the lower
esophagus leading to a closed LES, resembling a bird’s
beak (Fig. 3).
In 1997 de Oliveira et al. [68] described timed barium
esophagogram as a simple, noninvasive, and widely avail-
able barium technique for evaluating esophageal empty-
ing in patients with achalasia, which can provide
objective assessment after therapy as in many patients
with achalasia, symptom relief does not always parallel
esophageal emptying. The films in this technique are
taken at 1, 2 and 5 minutes after the last swallow of bar-
ium; the purpose of 2 min film is to assess interim
emptying (Fig. 4). The technique is simple to inter-
pret because both radiologists and gastroenterolo-
gists can accurately assess emptying. Emptying can
be assessed by the height time width of the barium
column or a qualitative estimate of emptying. This
method can be also used in predicting the success of treat-
ment in patients with achalasia, which will be discussed
later [68–71].Endoscopy
All patients with suspected achalasia should undergo
upper gastrointestinal endoscopy to exclude mechanical
obstruction or pseudoachalasia that can mimic achalasia
both clinically and manometrically [72, 73]. Pseudoacha-
lasia results from a tumor at the esophagogastric junc-
tion, therefore, this area needs to be examined carefully
during the procedure [1, 3]. At endoscopy, the esopha-
geal body may look normal, or dilated, atonic and often
tortuous. The mucosa looks normal, but sometimes it is
thickened or friable with even superficial ulcers second-
ary to chronic stasis or candida esophagitis. The LES is
closed even with insufflations of air, but the endoscope
can easily pass this area with gentle pressure. If a tumor
is suspected because of rapid progression of symptoms, or
the need of excess pressure to open the LES, repeated en-
doscopy examinations with biopsies and endoscopic ultra-
sound and CT chest are mandatory. A study by Mittal
et al. (2003), also showed that endoscopic ultrasound may
be helpful in further evaluation of the LES and ruling out
infiltrating tumor if there is stronger resistance on endo-
scopic evaluation [74].
Fig. 2 Three sub-types of achalasia on high resolution manometry. a Quiescent esophageal body (Type I); b isobaric pan-esophageal
pressurization (Type II); c simultaneous contractions (Type III)
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Fig. 3 Barium swallow. a Dilated esophagus with retained column of barium and “bird’s beaking” suggestive of achalasia. b End stage achalasia
with retained food, barium and tortuous esophagus
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tients undergoing endoscopic evaluation for dysphagia to
assess for eosinophilic esophagitis, biopsies are generally
not necessary if the endoscopic findings are characteristic
for achalasia [5]. However, it is important to note that it is
not uncommon to find an increased number of eosinophils
in patients with achalasia secondary to potential stasis in-
flammation [28, 75], and clinical presentation and classic
manometric findings might be necessary to help distinguish
the two diagnoses. The information on cancer risk in acha-
lasia is insufficient. There are many studies on this and the
great majority of them suggests a significantly increased risk
[76]; however, there are currently no recommendations for
surveillance of achalasia patients for esophageal cancer.
Differential diagnosis
A majority of patients are misdiagnosed as having reflux
disease given regurgitation. The differential diagnosis of
a patient with dysphagia and regurgitation includesGERD, pseudoachalasia (associated with malignancies or
secondary achalasia from extrinsic processes such as
prior tight fundoplication), iatrogenic achalasia (ob-
structive procedures for weight loss) and possibly eo-
sinophilic esophagitis. Tumors in the gastric cardia or
those infiltrating the myenteric plexus (adenocarcinoma
of the gastroesophageal junction, pancreatic, breast,
lung, or hepatocellular cancers) should be considered
highly in the differential based on findings on EGD and
manometry and if the clinical history is significant for
acute weight loss [72]. Infection by Trypanosoma Cruzi,
also known as Chagas’ disease, can also result in achala-
sia, but these patients often have other features of diffuse
enteric myenteric destruction, including megacolon,
heart disease, and neurologic disorders [77].
Management
Despite insight into the pathophysiology of achalasia,
the etiology of the disorder remains unknown; thus, it
Fig. 4 Timed barium swallow before and after pneumatic dilation showing retention of barium in the former and complete emptying post
effective therapy in the latter
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tive. If untreated, the disease course leads to a pro-
gressive stasis and dilation of the esophagus, which
results in increased risk of aspiration, weight loss,
and malnutrition. Current therapeutic options aim to
reduce LES pressure, relieve functional obstruction to
esophageal transit, and facilitate esophageal emptying.
Well-studied treatment options include oral pharma-
cologic agents, chemical denervation by endoscopic
injection of botulinum toxin, pneumatic dilation, andsurgical myotomy. More recently investigated endo-
scopic interventions include self-expanding metallic
stents and per-oral endoscopic myotomy (POEM)
[78–80]. These methods vary in their level of inva-
siveness and risk of adverse effects [81, 82].
Pharmacologic treatment
Oral pharmacologic therapies aim at relaxation of the
smooth muscle to lower LES pressure. Calcium channel
blockers and nitrates are the two most common agents
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anti-cholinergics (atropine, dicyclomine, cimetropium,
bromide), beta-adrenergic agonists (terbutaline), and
theophylline [11]. Calcium channel blockers inhibit cal-
cium entry into the cells, resulting in reduced esophageal
muscle contraction and a decrease in LES pressure by 13-
49 % [5]. Nifedipine is the most commonly used calcium
channel blocker for the treatment of achalasia. It is available
in a sublingual formulation with maximum effect seen at
20 to 45 min. Sublingual nifedipine (10-30 mg)
should be administered 30–45 min prior to meals and
at bedtime [11]. The efficacy of nifedipine largely var-
ies with symptom improvement observed in 0 % to
75 % of patients in clinical trials, but its use is largely
limited by side effects reported in up to 30 % of pa-
tients [11, 81].
Nitrates work by increasing NO concentration in
smooth muscle cells via cyclic GMP. Sublingual iso-
sorbide dinitrate has been shown to reduce LES pres-
sure by 30-65 %, resulting in symptom improvement
in 53 to 87 % of patients. The effect of nitrates is
more rapid than that of nifedipine, but has a shorter
duration; thus, sublingual isosorbide dinitrate (5 mg)
is commonly administered only 10 to 15 min before
meals [11].
In a study comparing the effect of sublingual nifedipine
to sublingual isosorbide dinitrate, both drugs decreased
LES pressure, but the effect of nitrate was slightly better
than that of nifidipine (65 % vs. 49 % respectively) [84]
Oral pharmacologic therapy is the least effective treatment
option for achalasia and rarely yields satisfactory long-
term symptom relief. Additionally, use is limited by side
effects such as headache, orthostasis, and pedal edema
[85]. Therefore, this treatment modality is reserved for pa-
tients who are not candidates for pneumatic dilation or
surgery, have failed botulinum toxin injections, or as a
bridge to more effective therapy [11].
Botulinum toxin treatment
Botulinum toxin (BT) was first used in achalasia patients
by Pasricha and his colleagues [2, 86, 87]. This toxin is
derived from Clostridium botulinum and causes paraly-
sis of voluntary and involuntary muscles by inhibiting
the release of acetylcholine from presynaptic vesicles.
Local injection of BT results in chemical denervation of
the LES; thus, improving esophageal emptying by coun-
terbalancing the selective loss of inhibitory neurons in
the myenteric plexus [2, 81]. BT A 80–100 Units are
injected through a 5-mm sclerotherapy needle into the
LES. Aliquots equaling 20 to 25 U of the toxin are
injected into each quadrant of the LES. Injection of BT
seems to be simple and safe, without carrying any risk of
perforation. Complications are minor and include transi-
ent chest pain (16-25 %), reflux symptoms (<5 %), andrare complications such as mediastinitis and allergic re-
actions related to egg protein [5, 88]. There is also con-
cern that repeated BT injections can induce an
inflammatory reaction that may obscure the mucosal-
muscular plane and increase surgical complications dur-
ing future surgical myotomy [82, 89–91].
Although initial symptom relief is observed in >75 % of
patients, the therapeutic effect wears off, and approxi-
mately 50 % of patients will require repeat injections at 6
to 24 month intervals, or additional treatment with pneu-
matic dilation (PD) or myotomy [1, 2, 87, 92]. Table 1 re-
flects the symptom response rate as well as percent of LES
pressure drop after treatment with BT over a period of
12 months in most valuable studies. Only a few studies
are available on the long-term efficacy of BT. Our initial
randomized trial found a one year success rate of 32 % in
achalasia patients treated with BT [2]. Annese et al. [93]
reported a success rate of 68 % at 24 months after receiv-
ing repeated BT injection, while Pasricha et al. [94] found
a 30 % efficacy rate after a mean follow-up of 2 years.
Post-treatment evaluations have revealed that neither pre-
treatment LES pressure, amplitude of esophageal contrac-
tions, nor duration of illness could be used to predict the
outcome of BT injection. Instead, young age and male
gender were found to adversely affect the outcome [94,
95]. Symptom relief was found to last up to 1 to 2 years
with a single injection in the elderly [96, 97]. Overall, BT
is recommended to be most effective in elderly patients, in
whom dilation or surgery represent a high risk.
Pneumatic dilation
Pneumatic dilation (PD) is the most effective non-
surgical treatment option for patients with achalasia [9].
It uses air to dilate the esophageal lumen and disrupt
the circular muscle fibers of the LES [1]. The most com-
monly used balloon is the Rigiflex dilator. Rigiflex bal-
loons come in three different diameters (3.0, 3.5, and
4.0 cm). Initial dilation with a 3.0 cm balloon is recom-
mended for most patients. The pressure required is usu-
ally 8–15 psi of air held for 15–60 s. The number of
dilation sessions depends on recurrence of symptoms
and there are scoring systems available such as the Eck-
ardt score system, which can be used to define patient’s
response to PD [98]. Patients undergo a post-procedure
gastrograffin study followed by barium esophagram to
rule out esophageal perforation [5].
Cumulatively, dilation with 3.0, 3.5, and 4.0 cm balloon
diameters results in good to excellent symptomatic relief
in 74 %, 86 %, and 90 % of treated patients, respectively,
with an average follow-up of 1.6 years [11]. Patients
often require repeat intervention over time due to de-
creased remission rates. In a study of 106 patients, Vela
et al. reported the success rate of single PD as 62 % at
6 months and 28 % at 6 years, compared to 90 % at
Table 1 Effect of botulinum toxin on achalasia
Study Method Number of patients
enrolled








Pasricha et al. [87] Randomized control trial 21 33 % 90 % 44 % ___
Fishman et al. [92] Prospective study 60 ___ 70 % ___ 36 %
Gordon et al. [123] Prospective study 16 ___ 75 % 48 % ___
Vaezi et al. [2] Randomized trial 24 1 % 60 % 50 % 32 %
Annese et al. [116] Randomized trial 16 49 % 100 % ___ 12.5 %
Pasricha et al. [94] Prospective study 31 45 % 90 % 64 % ___
Martinek et al. [124] Prospective cohort study 49 65 % 93 % ___ 41 %
Zaninotto et al. [125] Randomized controlled trial 40 ___ ___ 66 % 34 %
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a prospective study, Eckardt et al. treated 54 patients
with PD and reported an overall 5-year remission rate of
40 % and a 10-year remission rate of 36 % [95]. Other
studies have shown good to excellent symptom improve-
ment in 50-89 % of patients over a mean follow-up of
4 years [11, 100, 101].
Predictors of favorable clinical response to PD include
older age (>45 years), female gender, narrow esophagus,
LES pressure after dilation of <10 mmHg, increased
emptying on post-treatment timed barium esophagram,
and type II pattern on HRM. In younger males, it is rec-
ommended that the PD employing the 3.5 cm balloon or
surgical myotomy may be the best initial approach [5, 99].
Pneumatic dilation is well-tolerated with a rare but serious
complication of esophageal perforation in approximately
2 % of procedures [11]. Due to the risk of esophageal per-
foration, patients being considered for PD must be surgi-
cal candidates in case of perforation.
Our recent studies [69, 70, 100, 102] suggest timed
barium esophagogram as a better predictor of treat-
ment success after PD. We have found that in almost
70 % of the patients, the height of the barium column
at 5 min post-therapy correlates with symptom im-
provement (concordant group), while in others
esophageal emptying was poor despite reports of ex-
cellent symptom relief (discordant group). Nearly all
patients in discordant group failed the treatment
within 1 year after treatment, while 77 % of the con-
cordant group were still in symptom remission after
6 years of follow-up [69]. Therefore, it is suggested
that the timed barium esophagogram not only as-
sesses treatment shortly after therapy, it can also pre-
dict the poor response to the treatment if the patient
has retained barium post-pneumatic dilation.
Surgical myotomy
Surgical management of achalasia involves perform-
ing a Heller myotomy (HM), combined with a fundo-
plication to prevent reflux. Surgical myotomy wasoriginally performed via thoracotomy with good to
excellent results in 60-94 % of patients followed for
1–36 years [11]. This intervention evolved to be per-
formed with a laparotomy approach, then a thoraco-
scopic approach, and finally via laparoscopy that has
fallen in favor due to superior visualization of the
gastroesophageal junction, the ability to add an anti-
reflux procedure, decreased morbidity, shorter hos-
pital stay, and faster recovery [103].
A cumulative good to excellent clinical response
rate of 94 % has been reported for laparoscopic myot-
omy over a short period of time. Studies on long-
term outcome of myotomy are summarized in Table 2.
The major disadvantages of myotomy are incomplete
myotomy and the possibility of significant GERD.
Table 2 also shows the rate of developing GERD after
myotomy in the most valuable studies reported. In a
double-blind randomized trial, Richards et al. re-
ported abnormal acid exposure on pH monitoring in
47 % of patients without an anti-reflux procedure
compared to 9 % of patients who had a Dor fundopli-
cation [104]. While a concomitant anti-reflux proced-
ure is recommended [105], the type of fundoplication
(Dor vs. posterior Toupet) remains controversial with
recent meta-analysis showing significantly higher re-
currence rate of clinical regurgitation and pathological
acid reflux in the Dor fundoplication group [106].
Rebecchi et al. reported similar long-term reflux control
in patients who received a Heller myotomy plus floppy-
Nissen versus Dor fundoplication; however, those who
underwent Nissen fundoplication experienced more re-
currence of dysphagia [107]. Subsequently, multiple recent
randomized controlled trials comparing Heller myotomy
in conjunction with a Dor versus Toupet fundoplication
showed significant improvement in both dysphagia and
regurgitation symptoms regardless of the type of partial
fundoplication with dramatic improvements in Eckardt
scores [108, 109]. Patients undergoing Toupet fundoplica-
tion did have significantly better relative improvements in
the EORTC QLQ-OES18 (functional scale), but otherwise
Table 2 Long-term result of laparoscopic myotomy with fundoplications
Study Method Method of surgery Number of patients
enrolled




Bessell et al. [126] Prospective Laparoscopic HMb 167 5 years 77 % Not mentioned
Vella et al. [99], Retrospectivecohort 88 % Laparoscopic
and 12 % open HM
73 6 years 57 % 36 %
Dang et al. [127] Retrospective 81 % Laparoscopic
and 9 % open HM
22 3 years 76 % Not mentioned
Raiser et al. [128] Retrospective Laparoscopic or
thoracoscopic HM
35 1-4 years 97 % Not mentioned
Hunt et al. [129] Retrospective Laparoscopic HM 70 2.9 years 81 % 4.5 %
Frantzides et al. [130] Retrospective Laparoscopic HM 53 3 years 92 % 9 %
Zaninotto et al. [131] Prospective Laparoscopic HM 100 2 y 92 % 7 %
aGERD Gastroesophageal reflux disease; bHM Heller myotomy
Patel et al. Orphanet Journal of Rare Diseases  (2015) 10:89 Page 10 of 14no differences between the two anti-reflux repairs were
noted [109]. Thus, the optimum fundoplication proced-
ure after HM for achalasia remains controversial, but
given the likelihood of reflux symptoms after myotomy
despite added fundoplication, proton pump inhibitor
(PPI) therapy may be indicated in those who complain
of heartburn [5].
Possible treatment options after a failed myotomy in-
clude PD or a repeat surgical myotomy. A study of un-
treated achalasia patients and patients with failed
myotomy reports no increased risk of perforation with
performing PD after Heller myotomy. However, this
study also indicates that despite lower LES pressure, pa-
tients undergoing PD after failed myotomy do not do as
well as untreated cases [110]. Finally, laparoscopic sur-
gery used to be performed only on patients who relapsed
after graded PD; however, PD and surgical myotomy are
now offered as initial therapy for patients who are at low
surgical risk. Studies show best outcomes after PD in pa-
tients older than 40 years, women, those with narrow
esophageal diameter, and those with a type II pattern on
HRM [63, 69, 99, 111, 112], while surgery may be indi-
cated as the first line therapy for patients with tortuous
esophagus, esophageal diverticula, or previous surgery
on the gastroesophageal junction.
Per-oral endoscopic myotomy
Per-oral endoscopic myotomy (POEM) is an endo-
scopic approach to esophagomyotomy that was first re-
ported in porcine models by Pasricha et al. [79] and
then in humans by Inoue et al. [113]. Since its intro-
duction in humans in 2010, this novel approach has
been increasingly used at centers worldwide. POEM in-
volves an esophageal mucosal incision (approximately
10 cm proximal to esophagogastric junction) followed
by creation of a submucosal tunnel and dissection of
the muscle fibers beginning at 3 cm distal to the muco-
sal entry site and extending 2 cm into the cardia [114].
Since it is essential to prevent an inadequate myotomy,extension of the submucosal tunnel beyond the LES
into the cardia is confirmed via a retroflexed view with
visualization of the blue dye (used in the submucosal
injection). The incision is subsequently closed with
hemostatic clips or endoscopic suturing [114]. This
procedure is technically demanding and requires a cer-
tain level of training and expertise. However, treatment
success has been reported as high as 90 % with signifi-
cant decreases in LES pressure, decreased Eckardt
scores, and improved quality of life measurements with
low complication rates [115]. The main complication is
GERD that has been reported to occur in approxi-
mately 12 % of patients. Other rare potential complica-
tions include delayed bleeding, pneumomediastinum,
pneumothorax, pneumoperitoneum, and mucosal flap
perforation [114]. POEM appears to be a promising
intervention; however, current data is limited by small
study numbers and short-term follow-up.
Comparison of the procedures
Several randomized trials suggest that pneumatic dila-
tion is more effective than botulinum toxin [2, 116, 117].
Our study, which was one of the largest studies compar-
ing the outcome of two therapies, suggested that both
therapies are effective at 1 month, but PD results in sig-
nificantly better symptom improvement at 12 months
compared with BT (70 % vs. 32 % respectively) [2].
These findings indicate that botulinum toxin is inferior
to pneumatic dilation for sustained symptom relief
[118]. A study on cost-effectiveness of treatments also
suggests that in the long-term, PD is a more cost-
effective treatment for achalasia compared to BT [119].
Comparison of PD and HM also shows that there is
no difference in the early outcome of these treatments,
and the success rate of both methods decreases over
time (90 % vs. 89 % respectively at 6 months, to 44 % vs.
56 % at 6 years) [99]. Studies also suggest that laparo-
scopic myotomy is not a cost-effective therapy as the ini-
tial cost is too high [119]. However, HM has improved
Patel et al. Orphanet Journal of Rare Diseases  (2015) 10:89 Page 11 of 14cost-effectiveness and the difference between the two
treatment modalities decreases if the durability of HM is
>10 years given the likelihood of necessary repeated PD
treatments [120]. Laparoscopic HM is an effective treat-
ment modality in patients with achalasia who have failed
to respond to PD, as the 10-year remission rate in these
patients following myotomy is shown to be 77 % com-
pared to 72 % and 45 % in patients “successfully” treated
with a single PD and patients undergoing several dila-
tions respectively [121]. Overall, HM is the more durable
treatment for achalasia, but PD is more cost-effective. A
recent randomized trial comparing HM to PD showed
equivalent treatment outcome after two years of follow
up in 201 patients with achalasia [111] . Subsequently, a
comparative study between POEM and HM showed that
both interventions resulted in similar symptom and
physiology improvement, but POEM resulted in shorter
operative times and shorter hospitalizations [122].
A proposed algorithm for the management of patients
with achalasia is depicted in Fig. 5. The choice of initial
therapy should be guided by patients’ age, gender, prefer-
ence, and local institutional expertise. Surgical myotomy
and PD remain the key treatment options for patients.Fig. 5 Management algorithm for patients with achalasiaWhen deciding on myotomy vs PD, it is important to
consider the complications, durability, and cost-
effectiveness, as well as the experience of the surgeons
and gastroenterologists. Botulinum toxin therapy is
recommended for patients who are not surgical
candidates or are high-risk, and pharmacologic therapy
is reserved for patients who cannot undergo definitive
treatment or have failed botulinum toxin injections.Conclusions
Achalasia is a motor disorder of the esophagus charac-
terized by dysphagia, regurgitation, and chest pain. Al-
though it cannot be permanently cured, excellent
palliation is available in over 90 % of patients. As a result
of the advances in pneumatic dilation and laparoscopic
Heller myotomy, most patients with achalasia can now
choose between these two treatments. The injection of
botulinum toxin endoscopically into the LES is usually
reserved for elderly, or patients who are not candidates
for pneumatic dilation or surgery. In patients unrespon-
sive to graded pneumatic dilation, esophageal myotomy
via the laparoscopic method should be performed.
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